Jump to content

PSIL-001

Add links
From Wikipedia, the free encyclopedia
PSIL-001
Clinical data
Other namesPSIL001
Routes of
administration		Unspecified[1]
Drug classNon-hallucinogenic serotonin 5-HT1 receptor modulator

PSIL-001 is a non-hallucinogenic serotonin 5-HT1 receptor modulator which is under development for the treatment of depressive disorders, mood disorders, neurodegenerative disorders, and substance-related disorders.[1][2][3][4] Its route of administration is unspecified.[1] The drug's effects in animals have been described.[4] PSIL-001 is being developed by Psilera.[1][2] As of August 2022, it is in the preclinical research stage of development for all indications.[1][2] The drug is an analogue of dimethyltryptamine (DMT), but its exact chemical structure does not yet seem to have been disclosed.[3][1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "PSIL 001". AdisInsight. 29 August 2022. Retrieved 16 February 2025.
  2. ^ a b c "Delving into the Latest Updates on PSIL-001 with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. ^ a b "Psilera's New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders". BioSpace. 10 August 2022. Retrieved 16 February 2025.
  4. ^ a b "American Chemical Society – 263rd National Meeting and Exposition. Virtual/San Diego – March 20-24, 2022: Novel nonhallucinogenic DMT analogues as drug candidates for mental health and addiction disorders". Drugs of the Future. 47 (5): 387–398 (390). 2022. doi:10.1358/dof.2022.47.5.3432776. Novel nonhallucinogenic DMT analogues as drug candidates for mental health and addiction disorders [...] Aided by its proprietary BRAIN technology platform, which virtually screens and filters compounds for psychedelic potential at multiple receptors (especially 5-HT2A), the company has identified several novel derivatives of dimethyltryptamine (DMT) and psilocin (4-OH-DMT, psilocybin' [...] The identified derivatives include the lead compounds PSIL-002 (halogenated) and PSIL-001, 2 novel DMT analogues that are, therapeutically active and CNS-active. The most advanced lead compound, PSIL-002, did not induce hallucinogenic effects in mice at intraperitoneal doses up to 100 mg/kg (head-twitch response tests), while proving to be while proving to be safe and well tolerated. It produced therapeutic effects in several behavioral mouse models, including antidepressant effects (at 25 to 50 mg/kg; increased swimming and reduced immobility in forced swim tests), anxiolytic effects (at 25 to 100 mg/kg; increased socialization in prepulse inhibition tests) and cognitive effects (improved learning in repeat tests). In addition, when [...] In addition to PSIL-001 and PSIL-002, other new chemical entities with therapeutic potential have already been synthesized and preclinical testing was being planned. In parallel to this research, Psilera is developing new patient-friendly delivery systems of naturally occurring psychedelics with lower abuse potential, including a nonhallucinogenic transdermal patch formulation of DMT for social anxiety [...]
[edit]



Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=PSIL-001&oldid=1276000099"